Evidence map›Paper›PMID 32804929›Full record

ArticlePLoS computational biology2020

Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis.

Hongtao Yu, Sanchita Basu, K Melissa Hallow

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Stronger together: a cross-SIG perspective on improving drug development.Journal of pharmacokinetics and pharmacodynamics · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Salsolinol improves angiotensin II‑induced myocardial fibrosisExperimental and therapeutic medicine · 2023
    Article
  8. A systematic review of cardiacProgress in biomedical engineering (Bristol, England) · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hongtao YuSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0003-2278-4478
Sanchita BasuSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, Georgia, United States of America.
K Melissa HallowSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0002-8156-2245
University of Georgia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congestive heart failure is characterized by suppressed cardiac output and arterial filling pressure, leading to renal retention of salt and water, contributing to further volume overload. Mathematical modeling provides a means to investigate the integrated function and dysfunction of heart and kidney in heart failure. This study updates our previously reported integrated model of cardiac and renal functions to account for the fluid exchange between the blood and interstitium across the capillary membrane, allowing the simulation of edema. A state of heart failure with reduced ejection fraction (HF-rEF) was then produced by altering cardiac parameters reflecting cardiac injury and cardiovascular disease, including heart contractility, myocyte hypertrophy, arterial stiffness, and systemic resistance. After matching baseline characteristics of the SOLVD clinical study, parameters governing rates of cardiac remodeling were calibrated to describe the progression of cardiac hemodynamic variables observed over one year in the placebo arm of the SOLVD clinical study. The model was then validated by reproducing improvements in cardiac function in the enalapril arm of SOLVD. The model was then applied to prospectively predict the response to the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin, which has been shown to reduce heart failure events in HF-rEF patients in the recent DAPAHF clinical trial by incompletely understood mechanisms. The simulations predict that dapagliflozin slows cardiac remodeling by reducing preload on the heart, and relieves congestion by clearing interstitial fluid without excessively reducing blood volume. This provides a quantitative mechanistic explanation for the observed benefits of SGLT2i in HF-rEF. The model also provides a tool for further investigation of heart failure drug therapies.

Indexed as

Models, CardiovascularBenzhydryl CompoundsCardiomegalyExtracellular FluidGlucosidesHeartHeart FailureHemodynamicsHumansKidneyMyocytes, CardiacSodium-Glucose Transporter 2 InhibitorsStroke VolumeBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID32804929
PMCPMC7451992
OpenAlexW3063183644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.